Cargando…

Reduced annexin A6 expression promotes the degradation of activated epidermal growth factor receptor and sensitizes invasive breast cancer cells to EGFR-targeted tyrosine kinase inhibitors

BACKGROUND: The expression of annexin A6 (AnxA6) in AnxA6-deficient non-invasive tumor cells has been shown to terminate epidermal growth factor receptor (EGFR) activation and downstream signaling. However, as a scaffolding protein, AnxA6 may stabilize activated cell-surface receptors to promote cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koumangoye, Rainelli B, Nangami, Gladys N, Thompson, Pamela D, Agboto, Vincent K, Ochieng, Josiah, Sakwe, Amos M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922904/ https://www.ncbi.nlm.nih.gov/pubmed/24354805 http://dx.doi.org/10.1186/1476-4598-12-167

Ejemplares similares

Detachment of Breast Tumor Cells Induces Rapid Secretion of Exosomes Which Subsequently Mediate Cellular Adhesion and Spreading
por: Koumangoye, Rainelli B., et al.
Publicado: (2011)

Lapatinib-induced annexin A6 upregulation as an adaptive response of triple-negative breast cancer cells to EGFR tyrosine kinase inhibitors
por: Widatalla, Sarrah E, et al.
Publicado: (2019)

Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility
por: Whalen, Diva S., et al.
Publicado: (2019)

Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes
por: Ochieng, Josiah, et al.
Publicado: (2018)

Diverse Roles of Annexin A6 in Triple-Negative Breast Cancer Diagnosis, Prognosis and EGFR-Targeted Therapies
por: Korolkova, Olga Y., et al.
Publicado: (2020)

Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets
por: Korolkova, Olga Y., et al.
Publicado: (2020)

Fetuin‐A (alpha 2HS glycoprotein) modulates growth, motility, invasion, and senescence in high‐grade astrocytomas
por: Nangami, Gladys N., et al.
Publicado: (2016)

The rapid endocytic uptake of fetuin‐A by adherent tumor cells is mediated by Toll‐like receptor 4 (TLR4)
por: Thomas, Portia L., et al.
Publicado: (2020)

The α2-HeremansSchmid glycoprotein (AHSG) promotes growth in head and neck squamous cell carcinoma (HNSCC)
por: Thompson, Pamela D, et al.
Publicado: (2013)

DNPEP is not the only peptidase that produces SPAK fragments in kidney
por: Koumangoye, Rainelli, et al.
Publicado: (2017)

Shotgun proteomic analysis of human head and neck squamous cell carcinoma cell line SQ20B with diminished AHSG expression
por: Iyamu, Georgina, et al.
Publicado: (2014)

Hypoxia-Inducible Expression of Annexin A6 Enhances the Resistance of Triple-Negative Breast Cancer Cells to EGFR and AR Antagonists
por: Williams, Stephen D., et al.
Publicado: (2022)

NKCC1: Newly Found as a Human Disease-Causing Ion Transporter
por: Koumangoye, Rainelli, et al.
Publicado: (2020)

Association of calcium sensing receptor polymorphisms at rs1801725 with circulating calcium in breast cancer patients
por: Wang, Li, et al.
Publicado: (2017)

Reduced Expression of Annexin A6 Induces Metabolic Reprogramming That Favors Rapid Fatty Acid Oxidation in Triple-Negative Breast Cancer Cells
por: Williams, Stephen D., et al.
Publicado: (2022)

Novel Human NKCC1 Mutations Cause Defects in Goblet Cell Mucus Secretion and Chronic Inflammation
por: Koumangoye, Rainelli, et al.
Publicado: (2019)

KCC3a, a Strong Candidate Pathway for K(+) Loss in Alkalemia
por: Ferdaus, Mohammed Zubaerul, et al.
Publicado: (2022)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

The Prediction Of Epidermal Growth Factor Receptor Mutation And Prognosis Of EGFR Tyrosine Kinase Inhibitor By Serum Ferritin In Advanced NSCLC
por: Wu, Zhen, et al.
Publicado: (2019)

Epidermal growth factor receptor tyrosine kinase inhibitors
por: Ranson, M
Publicado: (2004)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors
por: Chen, Qi, et al.
Publicado: (2015)

Epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors combined with chemotherapy in first‐line treatment in an advanced non‐small cell lung cancer patient with EGFR sensitive mutation
por: Huang, Aimi, et al.
Publicado: (2016)

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
por: Choi, Yong Won, et al.
Publicado: (2017)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
por: Xie, Yalin, et al.
Publicado: (2021)

The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma
por: de Biase, Dario, et al.
Publicado: (2017)

Treating with Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) Accompanying Lower Incidence of Second Primary Cancers
por: Chou, Wen-Ru, et al.
Publicado: (2022)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

Fetuin-A Promotes 3-Dimensional Growth in LNCaP Prostate Cancer Cells by Sequestering Extracellular Vesicles to Their Surfaces to Act as Signaling Platforms
por: Ochieng, Josiah, et al.
Publicado: (2022)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
por: Chen, Yongshun, et al.
Publicado: (2016)

Epidermal growth factor receptor (EGFR)—tyrosine kinase inhibitors as a first-line treatment for postoperative recurrent and EGFR-mutated non-small-cell lung cancer
por: Moriya, Tetsuji, et al.
Publicado: (2021)

CDK4/6 signaling attenuates the effect of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer
por: Hara, Naofumi, et al.
Publicado: (2023)

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors
por: Chiang, Anne C., et al.
Publicado: (2020)

Future prospects of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and surgery for non-small cell lung cancer
por: Nagano, Tatsuya, et al.
Publicado: (2022)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

CD200-positive cancer associated fibroblasts augment the sensitivity of Epidermal Growth Factor Receptor mutation-positive lung adenocarcinomas to EGFR Tyrosine kinase inhibitors
por: Ishibashi, Masayuki, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_f0jcsfv0l9nvn0vnmb9vlglpp9